Skip to content
Peptigraph home

Ecnoglutide Phase 3 trial (NCT05813795)

A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
664
actual
Start
5 Apr 2023 (actual)
Primary completion
20 Jun 2024 (actual)
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Design

Arms and doses

NCT05813795 study arms
ArmTypeInterventionsDescription
C1- XW003 Low DosageExperimentalDrug: Ecnoglutide Low DosageXW003 with low dosage once weekly
C1-PlaceboPlacebo comparatorDrug: PlaceboMatched Placebo once weekly
C2- XW003 Medium DosageExperimentalDrug: Ecnoglutide Medium DosageXW003 with medium dosage once weekly
C2-PlaceboPlacebo comparatorDrug: PlaceboMatched Placebo once weekly
C3- XW003 High DosageExperimentalDrug: Ecnoglutide High DosageXW003 with high dosage once weekly
C3-PlaceboPlacebo comparatorDrug: PlaceboMatched Placebo once weekly
Endpoints

Primary endpoint

NCT05813795 primary outcomes
MeasureTime frame
Percent change in body weight from baselineWeek 40
Proportion of subjects with weight loss ≥5% from baselineWeek 40
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05813795 secondary outcomes
MeasureTime frame
Percent and absolute body weight change from baselineBaseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Proportion of subjects with weight loss ≥ 5%, 10%, 15% from baselineBaseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Change from baseline in BMIBaseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Change from baseline in waist and hip circumferencesBaseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.